ブルセラ症ワクチンの世界市場-2022-2029

市場力学

予測期間中、市場参加者の取り組みが市場の成長を支え続ける

市場プレイヤーは、動物の健康と福祉を維持するために、家畜のワクチン接種に関する意識を高めるために、低開発国で啓発プログラムを立ち上げることで、いくつかのイニシアチブを取っています。2018年12月、ベーリンガーインゲルハイムは、到達困難な地域で動物医療資源を利用できるようにすることで、重要な動物の健康課題に焦点を当てる「LastMile」イニシアチブを立ち上げました。このイニシアチブは、羊、山羊、牛などの反芻動物を対象としており、さらに家禽類にも拡大する予定です。同社は、アフリカの小規模農家に対する動物医療ソリューションのアクセス、利用可能性、認知度のギャップを埋めるため、Global Alliance for Livestock Veterinary Medicines（GALVmed）の支援を受け、BMGFがスポンサーとなって本イニシアチブを開始しました。

2019年2月、FAOは水産畜産省との連携により、牛のワクチン接種キャンペーンを開始しました。このキャンペーンは、3,000頭以上の牛を失う原因となった症候性炭疽の発生に対処するためのものです。FAOは、一般的になりつつある動物の病気との闘いから、2017年から規模を拡大し、約900万頭の動物を保護することを目標としています。約1,000人の地域ベースの動物保健員が訓練を受け、FAOの緊急家畜対応プログラムを通じて、定期検診や家畜へのワクチン接種を実施しています。さらに、インド政府は2019年9月、インドのマトゥーラから約18億米ドルの家畜ワクチン接種計画を宣言しました。この構想は、今後5年間で主にブルセラ症や口蹄疫（FMD）などの家畜伝染病を抑制することを目的としています。

世界のブルセラ症ワクチン市場レポートでは、約73の市場データ表、57の図、170ページの構成で提供しています

目次

第1章 調査手法と範囲

• 調査手法
• 市場の範囲

第2章 主な動向と発展

第3章 エグゼクティブサマリー

• 品種別市場内訳
• 治療法別市場内訳
• 診断別市場内訳
• 地域別市場内訳

第4章 市場力学

• 市場影響要因
  • 促進要因
  • 抑制要因
  • ビジネスチャンス
• 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• バリューチェーン分析
• 特許分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み

第7章 品種別

• 羊
• 牛
• ヤギ

第8章 治療法別

• 抗生物質
• ワクチン

第9章 診断別

• 血清学的検査
• 分子生物学的検査
• 骨髄生検
• 磁気共鳴画像法（MRI）
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他の欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 競合シナリオ
• 競合他社の戦略分析
• 市況/シェア分析
• M&A（合併・買収）分析

第12章 企業プロファイル

• AniCon Labor GmbH
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Bayer AG
• Boehringer Ingelheim International GmbH
• Biogenesis-Bago
• Calier & Biologicos Laverlam
• Colorado Serum Company
• Hester Biosciences Limited
• Heska Corporation
• Indian Immunologicals Ltd.
• Lohmann Animal Health
• Chengdu Agricultural Machinery Plant
• Lanzhou Biological Pharmaceutical Plant
• Inner Mongolia Biological Pharmaceutical Plant
• Chinese Academy of Agricultural Science

第13章 DataM

Market Overview

The global brucellosis vaccines market was valued at USD 323.45 million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 4.5% during the forecast period (2022-2029).

The livestock or farm animal's category encompasses cattle, sheep, and goats that are vaccinated to protect against brucellosis diseases. The first dose of this vaccine is given at the age of 4-8 months of calves. It is the most widely used vaccine around the world. The Livestock Vaccine Innovation Fund (LVIF) project collaborates between the J. Craig Venter Institute and the International Livestock Research Institute to promote this vaccine. The LVIF enables improved health of livestock, as farmers' livelihoods depend on livestock. LVIF is an initiative taken by the Bill & Melinda Gates Foundation, Global Affairs Canada, and International Development Research Center (IDRC). It represents a joint investment over five years to reinforce the production, development, and commercialization of innovative vaccines to prevent livestock diseases in sub-Saharan Africa and South and Southeast Asia. The rising prevalence of brucellosis diseases in livestock and the increasing consumption of meat products are some factors that are expected to propel market growth.

Market Dynamics: Initiatives by market players will continue supporting the growth of the market during the forecast period

The market players are taking several initiatives by launching awareness programs in underdeveloped countries to raise awareness about livestock vaccination to maintain animal health and welfare. In December 2018, Boehringer Ingelheim launched the 'LastMile' initiative to focus on crucial animal health challenges by making animal medical resources available in hard-to-reach areas. The initiative targets ruminants, such as sheep, goats, and cattle, and will further expand to poultry. The company started this initiative with support from the Global Alliance for Livestock Veterinary Medicines (GALVmed) and was sponsored by BMGF to bridge gaps in access, availability, and awareness of animal healthcare solutions for smallholder farmers in Africa.

In February 2019, FAO launched a cattle vaccination campaign through collaboration with the Ministry of Fisheries and Livestock. The campaign was intended to address the outbreak of symptomatic anthrax, which has caused the loss of more than 3,000 cattle. The FAO aims to protect nearly 9 million animals from combating increasingly common animal diseases, scaling up from 2017. Around 1,000 community-based animal health workers have been trained and are carrying-out routine check-ups and vaccinating livestock through FAO's Emergency Livestock Response Program. Additionally, the Indian government declared a nearly $1.8 billion livestock vaccination scheme in September 2019 from Mathura, India. This initiative is intended to control livestock diseases, primarily brucellosis and foot and mouth disease (FMD), in the next five years.

Market Segmentation: The cattle segment accounted for the highest share in global brucellosis vaccines market

Cattle contribute a significant share in the brucellosis vaccines market. The market players are continuously offering novel products for the cattle. In September 2018, Boehringer Ingelheim launched a new respiratory vaccine, Bovalto Respi Intranasal, for cattle to protect against viruses Parainfluenza 3 Virus (PI3V) and Bovine Respiratory Syncytial Virus (BRSV). In March 2015, Boehringer Ingelheim launched a new vaccine, Bovela against Bovine Viral Diarrhea (BVD), in Europe for active immunization of cattle against both genotypes of the virus (BVDV-1 and BVDV-2). Besides, Zoetis Inc., in April 2018, expanded its manufacturing and research unit to Suzhou, China, to focus on the vaccines for cattle, pigs, fish, and companion animals.

Based on the treatment, the brucellosis vaccine market has been bifurcated into vaccines and antibiotics. Vaccination plays a considerable role in maintaining the proper health of livestock. The high consumption of meat products globally is further contributing to the livestock vaccine's growth, including the brucellosis vaccines market. Therefore, it contributes a significant share in the development of the brucellosis vaccines market across the globe. Several companies are offering and continuously researching the field of brucellosis vaccine.

Geographical Penetration: North America is the dominating region during the forecast period

North America dominated the global brucellosis vaccines market and is expected to retain its position during the forecast period. The US contributed over XX% to the North American brucellosis vaccines market in 2021. Animal husbandry has been a substantial factor in increasing the demand for vaccination in the region. Biological research is encouraging the development of disease-specific vaccinations for animal welfare.

The Asia Pacific is estimated to grow at a considerable growth rate in the brucellosis vaccines market during the forecast period. This growth can be accredited to the continuous rise in meat consumption and trade in the region, especially in China. China's increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. Such huge stats for animal husbandry are expected to grow the brucellosis vaccines market during the forecast period.

Competitive Landscape:

The Brucellosis vaccines market is fragmented due to multiple companies' availability. Some of the major key players in the market are AbbVie, Inc., AstraZeneca PLC, Bayer AG, BeiGene, CARsgen Therapeutics, CStone Pharmaceuticals Co., Ltd. and GlaxoSmithKline PLC, among others. The key players are adopting various growth strategies, such as acquisitions, product launches, and collaborations, contributing to the growth of the Brucellosis Vaccines market globally. In July 2020, AstraZeneca and Merck & Co., Inc. announced that Lynparza (olaparib) had been approved in the European Union (EU) for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. This approval further provides the company with a significant opportunity to sustain a substantial European pancreatic cancer drugs market position. In June 2020, AbbVie collaborated with Jacobio Pharmaceuticals to develop and commercialize SHP2 inhibitors that act on an important node in cancer and immune cells. In January 2022, AbbVie Announced U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for the treatment of non-small cell lung cancer. In October 2021, US FDA approved Roche's Tecentriq as an adjuvant treatment for people with early non-small cell lung cancer. It is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting.

COVID-19 Impact: Negative impact on the global Brucellosis Vaccines market

The outbreak of COVID-19 has certainly impacted the global brucellosis vaccines market. The lockdown has compelled the veterinaries to close their operations, or even if the vets are open, the public was afraid to visit vets for vaccination during the meantime. Besides, the consumption of meat and dairy products has decreased during the outbreak, which, in turn, has impacted the expansion of livestock across the globe. Therefore, the brucellosis vaccines market is expected to foresee a considerable decline in 2020.

The global brucellosis vaccines market report would provide an access to approximately 73 market data tables, 57 figures and 170 pages

Table of Contents

Scope and Methodology

• 1.1. Research Methodology
• 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

• 3.1. Market Snippet by Species
• 3.2. Market Snippet by Treatment
• 3.3. Market Snippet by Diagnosis
• 3.4. Market Snippet by Region

4. Market Dynamics

• 4.1. Market impacting factors
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
• 4.2. Impact analysis

5. Industry Analysis

• 5.1. Porter's five forces analysis
• 5.2. Value chain analysis
• 5.3. Patent Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives

7. By Species

• 7.1. Introduction
  • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Species Segment
  • 7.1.2. Market attractiveness index, By Species Segment
• 7.2. Sheep *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 7.3. Cattle
• 7.4. Goat

8. By Treatment

• 8.1. Introduction
  • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Treatment Segment
  • 8.1.2. Market attractiveness index, By Treatment Segment
• 8.2. Antibiotics*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 8.3. Vaccines

9. By Diagnosis

• 9.1. Introduction
  • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Diagnosis Segment
  • 9.1.2. Market attractiveness index, By Diagnosis Segment
• 9.2. Serological Tests*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 9.3. Molecular Techniques
• 9.4. Bone Marrow Biopsy
• 9.5. Magnetic Resonance Imaging (MRI)
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key region-specific dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
  • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. South America
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
  • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.3.6.1. Brazil
    • 10.3.6.2. Argentina
    • 10.3.6.3. Rest of South America
• 10.4. Europe
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
  • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.4.6.1. Germany
    • 10.4.6.2. U.K.
    • 10.4.6.3. France
    • 10.4.6.4. Spain
    • 10.4.6.5. Italy
    • 10.4.6.6. Rest of Europe
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
  • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis

11. Competitive Landscape

• 11.1. Competitive scenario
• 11.2. Competitor strategy analysis
• 11.3. Market positioning/share analysis
• 11.4. Mergers and acquisitions analysis

12. Company Profiles

• 12.1. AniCon Labor GmbH*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Bayer AG
• 12.3. Boehringer Ingelheim International GmbH
• 12.4. Biogenesis-Bago
• 12.5. Calier & Biologicos Laverlam
• 12.6. Colorado Serum Company
• 12.7. Hester Biosciences Limited
• 12.8. Heska Corporation
• 12.9. Indian Immunologicals Ltd.
• 12.10. Lohmann Animal Health
• 12.11. Chengdu Agricultural Machinery Plant
• 12.12. Lanzhou Biological Pharmaceutical Plant
• 12.13. Inner Mongolia Biological Pharmaceutical Plant
• 12.14. Chinese Academy of Agricultural Science
• List not Exhaustive*

13. DataM

• 13.1. Appendix
• 13.2. About us and services
• 13.3. Contact us